A Phase 1, Non-Randomized, Open Label Study to Determine the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Regorafenib (Primary) ; Rifampicin
- Indications Solid tumours; Tuberculosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 18 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Mar 2011 New trial record